Abstract
Background and Objectives Post-stroke cognitive impairment (PSCI) is highly prevalent across multiple cognitive domains. Individualised PSCI prognosis has mainly been researched using outcomes not developed specifically for stroke (i.e., dementia risk). Further, existing models often use predictors not routinely available in electronic health records. Here, we develop and externally validate clinical prediction models for overall PSCI using a stroke-specific cognitive outcome using acute cognition and data routinely collected as part of stroke care.
Methods N=430 stroke survivors completed the Oxford Cognitive Screen (OCS) in acute care and at 6-month follow-up (binarized outcome; impaired vs unimpaired). Logistic regression models were fitted comprising both mandatory clinically-relevant (age, sex, stroke severity, education, stroke hemisphere, acute PSCI) and data-driven (acute mood difficulties, length of stay in acute care, multimorbidity) predictors using backward elimination (p < 0.10) on multiply imputed data. Internal validation used bootstrapping to obtain optimism-adjusted performance estimates. External validation used the optimism-adjusted C-Slope as a uniform shrinkage factor.
Results The overall PSCI model demonstrated good optimism-adjusted performance (C-Statistic=0.76 [95% CI=0.71–0.80]). In external validation, the overall PSCI model was comparable to development data (C-Statistic=0.74 [95% CI=0.67–0.79]). PSCI model performance did not vary by sex, but performed best in adults <60 years old (C-Statistic=0.76) with moderate-severe acute PSCI (C-Statistic=0.72). We further explored modelling of
Discussion Prediction models of stroke-specific cognition have the potential to offer more meaningful PSCI prognoses, including domain-specific cognitive recovery, compared to existing models focused on domain-general decline. The present model shows promise of generalisability with an initial good external validation performance of the PSCI model in a different stroke severity cohort. Future recalibration of domain-specific models would be beneficial to provide additional detailed predictions.
Competing Interest Statement
ND is a developer of the OCS but does not receive renumeration for its use.
Funding Statement
ND (Advanced Fellowship NIHR302224) and AK (DSE Award NIHR305153) are funded by NIHR.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study uses data that is openly available at DementiaPlatforms UK https://dementiasplatforms.uk/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.